1
The Scottish Intercollegiate Guidelines Network website is at http://www.sign.ac.uk. http://www.sign.ac.uk/
2
The American Diabetes Association. https://www.diabetes.org/
3
The Cochrane collaboration at http://www.cochrane.org/ helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.”. http://www.cochrane.org/
4
NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at https://www.evidence.nhs.uk/. https://www.evidence.nhs.uk/
5
The commercial but not-for-profit Trip database at http://www.tripdatabase.com claims to be "the internet’s premier source of evidence-based content”. http://www.tripdatabase.com/
6
The International Diabetes Federation (IDF) is at http://www.idf.org. http://www.idf.org/
7
The George Eliot Diabetes Care Team’s Alphabet Strategy website is at www.abcdiabetes.co.uk. http://www.abcdiabetes.co.uk/
8
The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from http://www.casp-uk.net/. https://casp-uk.net/casp-tools-checklists/
9
Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at http://www.go.warwick.ac.uk/values-basedpractice. http://valuesbasedpractice.org/
10
The European Association for the Study of Diabetes (EASD). http://www.easd.org/
11
Diabetes Care: 40 (Supplement 1). Diabetes Care 2017;40.https://0-care-diabetesjournals-org.pugwash.lib.warwick.ac.uk/content/40/Supplement_1
12
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 2015;373:2117–28. doi:10.1056/NEJMoa1504720
13
Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine 2017;376:2300–2.http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMc1701990
14
Effects of Liraglutide on Glycemic Control :Cleveland Clinic Journal of Medicine. Published Online First: 2015.http://www.mdedge.com/ccjm/clinical-edge/summary/obesity/effects-liraglutide-glycemic-control
15
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine 2017;:644–57.http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1611925#t=article
16
Nauck MA. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126–32. doi:10.2337/dc12-2504
17
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013;369:1317–26. doi:10.1056/NEJMoa1307684
18
Lipska KJ, Krumholz H, Soones T, et al. Polypharmacy in the Aging Patient. JAMA 2016;315. doi:10.1001/jama.2016.0299
19
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, et al. Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia. JAMA Internal Medicine Published Online First: 26 October 2015. doi:10.1001/jamainternmed.2015.5950
20
Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society 2016;64:543–52. doi:10.1111/jgs.14028
21
Hine J, Paterson H, Abrol E, et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. The Lancet Diabetes & Endocrinology 2015;3:503–4.http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858715002260?via%3Dihub
22
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine 2016;375:323–34. doi:10.1056/NEJMoa1515920
23
Scheen AJ. SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 2016;16. doi:10.1007/s11892-016-0789-4
24
Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology 2015;14. doi:10.1186/s12933-015-0260-x
25
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet Published Online First: December 2015. doi:10.1016/S0140-6736(15)01225-8
26
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research 2015;12:90–100. doi:10.1177/1479164114559852
27
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2016;375:1834–44. doi:10.1056/NEJMoa1607141
28
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy 2016;17:1581–3.http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
29
Dauriz M, Targher G, Laroche C, et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017;40:671–8. doi:10.2337/dc16-2016
30
Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology 2016;4:411–9. doi:10.1016/S2213-8587(16)00052-8
31
Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy 2016;17:1581–3.http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073
32
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2016;375:1834–44. doi:10.1056/NEJMoa1607141
33
Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine 2016;164. doi:10.7326/M15-2650
34
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 2015;373:2117–28. doi:10.1056/NEJMoa1504720
35
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine 2015;373:2247–57.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/2119957013/EA851E49618490DPQ/1?accountid=14888
36
Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective. Circulation 2017;136:249–59.https://0-www-ncbi-nlm-nih-gov.pugwash.lib.warwick.ac.uk/pubmed/28522450
37
Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018;61:58–65.https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4422-0
38
Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in child and adolescent. Pediatric Diabetes 2014;15:26–46.http://0-onlinelibrary.wiley.com.pugwash.lib.warwick.ac.uk/doi/10.1111/pedi.12179/epdf
39
Pediatric Diabetes. ;15.http://onlinelibrary.wiley.com/doi/10.1111/pedi.2014.15.issue-S20/issuetoc
40
Bangstad H-J, Danne T, Deeb L, et al. Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes 2009;10:82–99. doi:10.1111/j.1399-5448.2009.00578.x
41
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber Published Online First: 2016.http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
42
ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. Prescriber Published Online First: 2016.http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/
43
Rang H. Pharmacokinetics. In: Rang & Dale’s pharmacology. Edinburgh: : Elsevier/Churchill Livingstone 2012. 123–31.https://contentstore.cla.co.uk/secure/link?id=1d4bfbd8-c343-e611-80bd-0cc47a6bddeb
44
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017;60:1385–9.https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4301-8
45
Young LA, Buse JB, Weaver MA, et al. Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. JAMA Internal Medicine 2017;177. doi:10.1001/jamainternmed.2017.1233
46
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008;358:2545–59.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223930983?accountid=14888
47
Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. Annals of Internal Medicine 2017;166. doi:10.7326/M16-1901
48
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2015;373:232–42.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1696912909?accountid=14888
49
Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine Published Online First: 2017.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1931756550?accountid=14888
50
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013;369:1317–26.https://0-www-nejm-org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684
51
Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine 2008;358:580–91.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223923658?accountid=14888
52
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 2015;373:2117–28. doi:10.1056/NEJMoa1504720
53
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–307. doi:10.1007/s00125-016-4065-6
54
The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2008;358:2560–72.https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223924651/fulltextPDF/4EC80B054DE144D4PQ/1?accountid=14888
55
Chen L, Pei J-H, Kuang J, et al. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism 2015;64:338–47.http://www.metabolismjournal.com/article/S0026-0495(14)00312-6/fulltext
56
Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. The Lancet 2004;363:1589–97.https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673604162028
57
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008;358:2545–59. doi:10.1056/NEJMoa0802743
58
Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The Lancet Diabetes & Endocrinology 2017;5:887–97. doi:10.1016/S2213-8587(17)30317-0
59
Complications of Diabetes Mellitus | InTechOpen. https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus
